Defining the level of evidence for technology adoption in the localized prostate cancer pathway

Urologic Oncology: Seminars and Original Investigations

Volumn 32, Issue 6, 2014, Pages 924-930

  Valerio, Massimo ^a,b,c   El Shater Bosaily, Ahmed ^a,b   Emberton, Mark ^a,b   Ahmed, Hashim U ^a,b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Focal therapy; Health technology assessment; MRI; Prostate cancer; Targeted biopsy; Trials

Indexed keywords

CANCER CONTROL; CANCER DIAGNOSIS; HEALTH CARE QUALITY; HUMAN; MEDICAL TECHNOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; REVIEW; STUDY DESIGN; TISSUE PRESERVATION; TRANSRECTAL ULTRASONOGRAPHY; TUMOR ABLATION; IMAGE GUIDED BIOPSY; MALE; PATHOLOGY; PROCEDURES; PROSTATE; PROSTATIC NEOPLASMS; RADIOTHERAPY; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY;

ANTIANDROGEN;

ANDROGEN ANTAGONISTS; HUMANS; IMAGE-GUIDED BIOPSY; MALE; PROSTATE; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOTHERAPY; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 84905222343     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2013.10.008     Document Type: Review

References (46)

1. Moyer V.A. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2012, 17:120-134.
2. Wolf A.M., Wender R.C., Etzioni R.B., et al. American Cancer Society guideline for the early detection of prostate cancer: update 2010. CA Cancer J Clin 2010, 60:70-98.
3. Basch E., Oliver T.K., Vickers A., et al. Screening for prostate cancer with prostate-specific antigen testing: American Society of Clinical Oncology provisional clinical opinion. J Clin Oncol 2012, 20:3020-3025.
4. Carter H.B., Albertsen P.C., Barry M.J., et al. Early detection of prostate cancer: AUA guideline. J Urol 2013, 190:419-426.
5. Eggener S.E., Scardino P.T., Carroll P.R., et al. Focal therapy for localized prostate cancer: a critical appraisal of rationale and modalities. J Urol 2007, 178:2260-2267.
6. Murphy D.G., Walton T.J., Connolly S., Costello A.J. Focal therapy for localised prostate cancer: are we asking the correct research questions?. BJU Int 2012, 109:1-3.
7. Philipps BBC, Sackett D, et al. Levels of evidence and grades of recommendation. Oxford Centre for Evidence-Based Medicine Web Site. http://www.cebm.net/index.aspx?=o1025 [accessed 14.12.12.
8. Cook J.A. The challenges faced in the design, conduct and analysis of surgical randomised controlled trials. Trials 2009, 10:9.
9. Patel S.G., Penson D.F., Pabla B., et al. National trends in the use of partial nephrectomy: a rising tide that has not lifted all boats. J Urol 2012, 187:816-821.
10. Pizzocaro G., Algaba F., Horenblas S., et al. EAU penile cancer guidelines 2009. Eur Urol 2010, 57:1002-1012.
11. Balshem H., Helfand M., Schunemann H.J., et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol 2011, 64:401-406.
12. Ahmed H.U., Arya M., Freeman A., Emberton M. Do low-grade and low-volume prostate cancers bear the hallmarks of malignancy?. Lancet Oncol 2012, 13:e509-e517.
13. Loeb S., Vellekoop A., Ahmed H.U., et al. Systematic review of complications of prostate biopsy. Eur Urol 2013.
14. Djavan B., Waldert M., Zlotta A., et al. Safety and morbidity of first and repeat transrectal ultrasound guided prostate needle biopsies: results of a prospective European prostate cancer detection study. J Urol 2001, 166:856-860.
15. Bossuyt P.M., Irwig L., Craig J., Glasziou P. Comparative accuracy: assessing new tests against existing diagnostic pathways. Br Med J 2006, 6(332):1089-1092.
16. Ahmed H.U., Kirkham A., Arya M., et al. Is it time to consider a role for MRI before prostate biopsy?. Nat Rev Clin Oncol 2009, 6:197-206.
17. Puech P., Huglo D., Petyt G., Lemaitre L., Villers A. Imaging of organ-confined prostate cancer: functional ultrasound, MRI and PET/computed tomography. Curr Opin Urol 2009, 19:168-176.
18. Villers A., Puech P., Mouton D., Leroy X., Ballereau C., Lemaitre L. Dynamic contrast enhanced, pelvic phased array magnetic resonance imaging of localized prostate cancer for predicting tumor volume: correlation with radical prostatectomy findings. J Urol 2006, 176:2432-2437.
19. Bossuyt P.M., Reitsma J.B., Bruns D.E., et al. The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration. Ann Intern Med 2003, 7:W1-W12.
20. Lijmer J.G., Mol B.W., Heisterkamp S., et al. Empirical evidence of design-related bias in studies of diagnostic tests. J Am Med Assoc 1999, 15:1061-1066.
21. http://www.ctu.mrc.ac.uk/research_areas/study_details.aspx?s=126.
22. Crawford E.D., Rove K.O., Barqawi A.B., et al. Clinical-pathologic correlation between transperineal mapping biopsies of the prostate and three-dimensional reconstruction of prostatectomy specimens. Prostate 2012, 73:778-787.
23. Lecornet E., Ahmed H.U., Hu Y., et al. The accuracy of different biopsy strategies for the detection of clinically important prostate cancer: a computer simulation. J Urol 2012, 188:974-980.
24. Moore C.M., Robertson N.L., Arsanious N., et al. Image-guided prostate biopsy using magnetic resonance imaging-derived targets: a systematic review. Eur Urol 2013, 63:125-140.
25. Moore C.M., Kasivisvanathan V., Eggener S., et al. Standards of reporting for MRI-targeted biopsy studies (START) of the prostate: recommendations from an International Working Group. Eur Urol 2013, 64:544-552.
26. Craig P., Dieppe P., Macintyre S., Michie S., Nazareth I., Petticrew M. Developing and evaluating complex interventions: the new Medical Research Council guidance. Br Med J 2008, 337:a1655.
27. McCulloch P., Altman D.G., Campbell W.B., et al. No surgical innovation without evaluation: the IDEAL recommendations. Lancet 2009, 26:1105-1112.
28. McCulloch P., Cook J.A., Altman D.G., Heneghan C., Diener M.K. IDEAL framework for surgical innovation 1: the idea and development stages. Br Med J 2013, 346:f3012.
29. Ergina P.L., Barkun J.S., McCulloch P., Cook J.A., Altman D.G. IDEAL framework for surgical innovation 2: observational studies in the exploration and assessment stages. Br Med J 2013, 346:f3011.
30. Cook J.A., McCulloch P., Blazeby J.M., Beard D.J., Marinac-Dabic D., Sedrakyan A. IDEAL framework for surgical innovation 3: randomised controlled trials in the assessment stage and evaluations in the long term study stage. Br Med J 2013, 346:f2820.
31. http://www.fda.gov/Drugs/NewsEvents/ucm348372.htm.
32. Wilt T.J., Brawer M.K., Jones K.M., et al. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 2012, 19:203-213.
33. Nguyen C.T., Jones J.S. Focal therapy in the management of localized prostate cancer. BJU Int 2011, 107:1362-1368.
34. Valerio M., Ahmed H.U., Emberton M., et al. The role of focal therapy in the management of localised prostate cancer: a systematic review. Eur Urol 2013, 10.1016/j.eururo.2013.05.048. [Epub ahead of print].
35. Hoang A.N., Volkin D., Yerram N.K., et al. Image guidance in the focal treatment of prostate cancer. Curr Opin Urol 2012, 22:328-335.
36. Resnick M.J., Koyama T., Fan K.H., et al. Long-term functional outcomes after treatment for localized prostate cancer. N Engl J Med 2013, 31:436-445.
37. Thompson I., Thrasher J.B., Aus G., et al. Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol 2007, 177:2106-2131.
38. Dickinson L., Ahmed H.U., Kirkham A., et al. A multi-centre prospective development study evaluating focal therapy using high intensity focused ultrasound for localised prostate cancer: the INDEX study. Contemp Clin Trials 2013, 36:68-80.
39. Federal Coordinating Council for comparative effectiveness research report to the President and the Congress. June 30, 2009.
40. Crook J.M., Gomez-Iturriaga A., Wallace K., et al. Comparison of health-related quality of life 5 years after SPIRIT: surgical prostatectomy versus interstitial radiation intervention trial. J Clin Oncol 2011, 1:362-368.
41. Donnelly B.J., Saliken J.C., Brasher P.M., et al. A randomized trial of external beam radiotherapy versus cryoablation in patients with localized prostate cancer. Cancer 2010, 15:323-330.
42. Chin J.L., Ng C.K., Touma N.J., et al. Randomized trial comparing cryoablation and external beam radiotherapy for T2C-T3B prostate cancer. Prostate Cancer Prostatic Dis 2008, 11:40-45.
43. Godwin M., Ruhland L., Casson I., et al. Pragmatic controlled clinical trials in primary care: the struggle between external and internal validity. BMC Med Res Methodol 2003, 22:28.
44. Gaus W., Muche R. Is a controlled randomised trial the non-plus-ultra design? A contribution to discussion on comparative, controlled, non-randomised trials. Contemp Clin Trials 2013, 35:127-132.
45. Relton C., Torgerson D., O'Cathain A., Nicholl J. Rethinking pragmatic randomised controlled trials: introducing the cohort multiple randomised controlled trial design. Br Med J 2010, 340:c1066.
46. Lilford R.J., Braunholtz D.A., Greenhalgh R., Edwards S.J. Trials and fast changing technologies: the case for tracker studies. Br Med J 2000, 1:43-46.